Diagnostic potential of monoclonal antibodies specific to the unique O-antigen of multidrug-resistant epidemic Escherichia coli clone ST131-O25b:H4.
The Escherichia coli lineage sequence type 131 (ST131)-O25b:H4 is a globally spread multidrug-resistant clone responsible for a great proportion of extraintestinal infections. Driven by the significant medical needs associated with this successful pathogenic lineage, we generated murine monoclonal antibodies (MAbs) against its lipopolysaccharide (LPS) O25b antigen in order to develop quick diagnostic tests. Murine monoclonal antibodies were generated by immunizing mice with whole killed nonencapsulated ST131-O25b E. coli cells and screening hybridoma supernatants for binding to purified LPS molecules obtained from an E. coli ST131-O25b clinical isolate. The MAbs selected for further study bound to the surface of live E. coli O25b strains irrespective of the capsular type expressed, while they did not bind to bacteria or purified LPS from other serotypes, including the related classical O25 antigen (O25a). Using these specific MAbs, we developed a latex bead-based agglutination assay that has greater specificity and is quicker and simpler than the currently available typing methods. The high specificities of these MAbs can be explained by the novel structure of the O25b repeating unit elucidated in this article. Based on comparative analysis by nuclear magnetic resonance (NMR) and mass spectrometry, the N-acetyl-fucose in the O25a O-antigen had been replaced by O-acetyl-rhamnose in the O25b repeating unit. The genetic determinants responsible for this structural variation were identified by aligning the corresponding genetic loci and were confirmed by trans-complementation of a rough mutant by the subserotype-specific fragments of the rfb operons.
Arsanis Biosciences GmbH, Helmut Qualtinger Gasse 2, Vienna, Austria.
Valéria
V
Szijártó
Department of Immunochemistry, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Jolanta
J
Lukasiewicz
Department of Immunochemistry, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Tomasz K
TK
Gozdziewicz
Arsanis Biosciences GmbH, Helmut Qualtinger Gasse 2, Vienna, Austria.
Zoltán
Z
Magyarics
Arsanis Biosciences GmbH, Helmut Qualtinger Gasse 2, Vienna, Austria.
Eszter
E
Nagy
Arsanis Biosciences GmbH, Helmut Qualtinger Gasse 2, Vienna, Austria gabor.nagy@arsanis.com.
Gábor
G
Nagy
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000276:immunology; D004927:Escherichia coli Infections / Q000175:diagnosis* / Q000276:immunology; D007114:Immunization; D007841:Latex Fixation Tests; D051379:Mice; D008969:Molecular Sequence Data; D019081:O Antigens / Q000235:genetics* / Q000276:immunology* / Q000648:ultrastructure
D000911:Antibodies, Monoclonal; D001426:Bacterial Proteins; D019081:O Antigens; C079397:rfb protein, Bacteria